Core Viewpoint - The Trump administration's recent tariffs have significantly impacted the stock market, with pharmaceuticals and biotech being relatively less affected compared to other sectors [1][2]. Industry Impact - The stock market experienced one of its worst trading days, with the S&P 500 dropping by 4.8%, while Catalyst Pharmaceuticals and Veeva Systems saw smaller declines of 1.5% and 2%, respectively. Notably, Amgen and AstraZeneca reported gains of 1.5% and 2.4% [2]. - The pharmaceutical sector was notably absent from the list of tariffs, which had initially included a proposed 25% duty on foreign pharmaceutical manufacturers [3][4]. Future Considerations - The exemption from tariffs is temporary, and there are indications that the administration may soon impose tariffs specifically targeting pharmaceutical exports [4][5]. - The pharmaceutical industry has powerful lobbyists advocating for reduced tariffs, which may have influenced the temporary exemption [5][6]. Regulatory Developments - Despite the looming threat of tariffs, the pharmaceutical industry continues to announce positive developments, such as Amgen's FDA approval for its Uplizna drug to treat IgG4-related disease, marking a significant advancement for patients [9][10]. - The approval of Uplizna is expected to reduce reliance on long-term steroid use for patients, highlighting the industry's ongoing commitment to regulatory approvals and medication development [10].

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 3:Veeva Systems Inc. (VEEV) : This cloud-based software provider has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.Veeva's shares gained 6.4% over the last three months compared with the S&P 500’s decline of 5.2%. The company possesses a Momentum Score of B.BNP Paribas SA (BNPQY) : This banking and financial products a ...

Core Insights - Veeva Systems has announced the launch of Veeva SiteVault CTMS, a clinical trial management system designed to enhance research site efficiency and integrate seamlessly with sponsors [1][2] - The system will be available for free to over 90% of research sites, specifically those managing up to 20 concurrent active studies, with an initial release planned for August 2025 [2] Group 1: Product Features and Benefits - Veeva SiteVault CTMS integrates with SiteVault eISF and SiteVault eConsent, allowing comprehensive management of clinical trials within a single system [1] - The integration with Veeva's Clinical Platform facilitates seamless bidirectional data flow between sites and sponsors, reducing manual processes and increasing efficiency [1][2] - The streamlined user experience provided by Veeva SiteVault is expected to enhance the speed of clinical trials, benefiting patients [2] Group 2: Company Commitment and Market Position - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [3] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [3]

Company Overview - Veeva Systems Inc. announced Veeva CRM Pulse, a data subscription service providing quarterly healthcare professional access and multichannel engagement metrics for the life sciences industry [1] - The service is currently available for Veeva's CRM customers, covering 2024 quarterly data across multiple countries including the US, Canada, and several European and Asian nations [2] - The introduction of CRM Pulse is expected to significantly enhance the Veeva Data Cloud product category, thereby boosting overall business performance [3] Financial Performance - Following the announcement of CRM Pulse, Veeva's shares increased by nearly 7.9% [4] - The company has a market capitalization of $38.34 billion and an earnings yield of 2.9%, which is favorable compared to the industry's negative yield [5] - In the last reported quarter, Veeva delivered an earnings surprise of 10.1% [5] Strategic Significance - Management believes that CRM Pulse will improve global segmentation and targeting, enhancing the value of data for commercial operations [6] - The latest availability of healthcare professional access data is seen as a significant milestone for Veeva Systems, expected to boost its business [8] Industry Prospects - The global healthcare analytics market was valued at $43.1 billion in 2023 and is projected to grow at a CAGR of 21.1% from 2024 to 2030, driven by technological advancements and the need for improved patient care [7]